This HTML5 document contains 57 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
n6	http://linked.opendata.cz/resource/mesh/concept/
rdfs	http://www.w3.org/2000/01/rdf-schema#
n7	http://linked.opendata.cz/resource/fda-spl/ingredient/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n5	http://linked.opendata.cz/ontology/mesh/
owl	http://www.w3.org/2002/07/owl#
nci	http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#
n8	http://linked.opendata.cz/resource/ndfrt/ingredient/
xsdh	http://www.w3.org/2001/XMLSchema#

Statements

Subject Item

nci:C1796

rdf:type

owl:Class

rdfs:label

Vorinostat

rdfs:subClassOf

nci:C1946 _:vb716172 _:vb716173 _:vb716174 _:vb716170 _:vb716171

nci:A7

nci:C16682

nci:A8

nci:C63923

nci:P106

Pharmacologic Substance Organic Chemical

nci:P108

Vorinostat

nci:P175

701852

nci:P207

C0672708

nci:P210

149647-78-9

nci:P302

Cutaneous T-cell Lymphoma

nci:P319

58IFB293JI

nci:P322

FDA

nci:P325

<n0:ComplexDefinition xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:def-definition>A drug that is used to treat cutaneous T-cell lymphoma that does not get better, gets worse, or comes back during or after treatment with other drugs. It is also being studied in the treatment of other types of cancer. Vorinostat is a type of histone deacetylase inhibitor.</n0:def-definition><n0:def-source>NCI-GLOSS</n0:def-source></n0:ComplexDefinition>

nci:P329

37944

nci:P330

37944

nci:P350

C14H20N2O3

nci:P366

Suberoylanilide_Hydroxamic_Acid

nci:P90

<n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Zolinza</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>NCI-GLOSS</n0:term-source><n0:source-code>CDR0000514187</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>vorinostat</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>NCI-GLOSS</n0:term-source><n0:source-code>CDR0000455153</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>SAHA</n0:term-name><n0:term-group>AB</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>VORINOSTAT</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>FDA</n0:term-source><n0:source-code>58IFB293JI</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>suberoylanilide hydroxamic acid</n0:term-name><n0:term-group>SY</n0:term-group><n0:term-source>NCI-GLOSS</n0:term-source><n0:source-code>CDR0000044908</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Suberoylanilide Hydroxamic Acid</n0:term-name><n0:term-group>CN</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>N-Hydroxy-N&#39;-phenyloctanediamide</n0:term-name><n0:term-group>SN</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>SAHA</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>NCI-GLOSS</n0:term-source><n0:source-code>CDR0000455152</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Suberanilohydroxamic Acid</n0:term-name><n0:term-group>SY</n0:term-group><n0:term-source>DCP</n0:term-source><n0:source-code>09559</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Suberanilohydroxamic Acid</n0:term-name><n0:term-group>CN</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>L-001079038</n0:term-name><n0:term-group>CN</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Vorinostat</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Zolinza</n0:term-name><n0:term-group>BR</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm>

nci:P97

<n0:ComplexDefinition xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:def-definition>A synthetic hydroxamic acid derivative with antineoplastic activity. Vorinostat, a second generation polar-planar compound, binds to the catalytic domain of the histone deacetylases (HDACs). This allows the hydroxamic moiety to chelate zinc ion located in the catalytic pockets of HDAC, thereby inhibiting deacetylation and leading to an accumulation of both hyperacetylated histones and transcription factors. Hyperacetylation of histone proteins results in the upregulation of the cyclin-dependant kinase p21, followed by G1 arrest. Hyperacetylation of non-histone proteins such as tumor suppressor p53, alpha tubulin, and heat-shock protein 90 produces additional anti-proliferative effects. This agent also induces apoptosis and sensitizes tumor cells to cell death processes. Vorinostat crosses the blood-brain barrier.</n0:def-definition><n0:def-source>NCI</n0:def-source></n0:ComplexDefinition>

nci:code

C1796

owl:sameAs

n7:58IFB293JI n8:N0000179580

n5:hasConcept

n6:M0288128

Subject Item

_:vb716170

rdf:type

owl:Restriction

owl:onProperty

nci:R125

owl:someValuesFrom

nci:C40738

Subject Item

_:vb716171

rdf:type

owl:Restriction

owl:onProperty

nci:R125

owl:someValuesFrom

nci:C26044

Subject Item

_:vb716172

rdf:type

owl:Restriction

owl:onProperty

nci:R146

owl:someValuesFrom

nci:C16682

Subject Item

_:vb716173

rdf:type

owl:Restriction

owl:onProperty

nci:R124

owl:someValuesFrom

nci:C40577

Subject Item

_:vb716174

rdf:type

owl:Restriction

owl:onProperty

nci:R125

owl:someValuesFrom

nci:C20150